NVO Novo Nordisk

   By Dominic Chopping 
 

Danish insulin maker Novo Nordisk A/S (NVO) said Friday it is investing DKK550 million in a new research and development facility in Bagsvaerd, Denmark.

 
   MAIN FACTS: 

-The purification plant will expand the company's capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs under development.

-The pilot plant will be fully operational by late 2016 and will be run by CMC Supply (Chemistry, Manufacturing and Control Supply); a unit within Novo Nordisk R&D.

-At 0820 GMT shares traded 0.9% lower at DKK245.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires